ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,69
0,14%
Dow Jones
43 297,03
0,91%
DAX
19 848,77
-0,34%
Brent Oil
73,375
0,12%
Bitcoin
98 798,31
-0,51%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Senti Biosciences Inc (SNTI)

  7. Senti Biosciences Inc (SNTI) Actualités

SNTI

Senti Biosciences (SNTI)

Senti Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SNTI
DateHeureSourceTitreSymboleSociété
16/12/202414h00GlobeNewswire Inc.Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest TherapeuticsNASDAQ:SNTISenti Biosciences Inc
04/12/202402h00GlobeNewswire Inc.Senti Biosciences Announces New Employment Inducement GrantsNASDAQ:SNTISenti Biosciences Inc
02/12/202413h10GlobeNewswire Inc.Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity FinancingNASDAQ:SNTISenti Biosciences Inc
02/12/202413h02GlobeNewswire Inc.Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AMLNASDAQ:SNTISenti Biosciences Inc
02/12/202413h00GlobeNewswire Inc.Senti Bio Appoints Fran Schulz to Board of DirectorsNASDAQ:SNTISenti Biosciences Inc
14/11/202422h05GlobeNewswire Inc.Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate HighlightsNASDAQ:SNTISenti Biosciences Inc
03/09/202414h15GlobeNewswire Inc.Senti Bio to Participate in Upcoming Investor ConferencesNASDAQ:SNTISenti Biosciences Inc
13/08/202422h05GlobeNewswire Inc.Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline HighlightsNASDAQ:SNTISenti Biosciences Inc
05/08/202414h05GlobeNewswire Inc.Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202NASDAQ:SNTISenti Biosciences Inc
16/07/202414h30GlobeNewswire Inc.Senti Bio Announces Reverse Stock SplitNASDAQ:SNTISenti Biosciences Inc
01/07/202414h05GlobeNewswire Inc.Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell TherapyNASDAQ:SNTISenti Biosciences Inc
29/05/202422h14Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SNTISenti Biosciences Inc
29/05/202422h09Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNTISenti Biosciences Inc
29/05/202422h07Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SNTISenti Biosciences Inc
17/05/202423h19Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SNTISenti Biosciences Inc
17/05/202423h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNTISenti Biosciences Inc
13/05/202414h15GlobeNewswire Inc.Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaNASDAQ:SNTISenti Biosciences Inc
09/05/202422h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNTISenti Biosciences Inc
09/05/202422h05GlobeNewswire Inc.Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate HighlightsNASDAQ:SNTISenti Biosciences Inc
30/04/202414h05GlobeNewswire Inc.Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)NASDAQ:SNTISenti Biosciences Inc
21/03/202421h05GlobeNewswire Inc.Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsNASDAQ:SNTISenti Biosciences Inc
05/01/202422h05GlobeNewswire Inc.Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical ProgramNASDAQ:SNTISenti Biosciences Inc
22/12/202312h30GlobeNewswire Inc.Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaNASDAQ:SNTISenti Biosciences Inc
13/11/202322h15GlobeNewswire Inc.Senti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesNASDAQ:SNTISenti Biosciences Inc
06/11/202322h05GlobeNewswire Inc.Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in ChinaNASDAQ:SNTISenti Biosciences Inc
31/10/202314h06GlobeNewswire Inc.Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual MeetingNASDAQ:SNTISenti Biosciences Inc
27/09/202315h05GlobeNewswire Inc.Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 MeetingNASDAQ:SNTISenti Biosciences Inc
26/09/202322h05GlobeNewswire Inc.Senti Bio to Participate in Upcoming ConferencesNASDAQ:SNTISenti Biosciences Inc
11/08/202314h35GlobeNewswire Inc.Senti Bio Announces Second Quarter 2023 Results and Pipeline UpdatesNASDAQ:SNTISenti Biosciences Inc
10/08/202314h35GlobeNewswire Inc.Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon PartnersNASDAQ:SNTISenti Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:SNTI

Dernières Valeurs Consultées

LSE
XN89
Morg.st.b.v 28
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés